Stocktoria
Fortress Biotech, Inc. FBIO
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2011-11-17
Fortress Biotech, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -111.0% | -191.4% | -168.4% | -268.8% | -274.1% |
| Net margin | 10.8% | -79.8% | -71.7% | -114.3% | -94.1% |
| FCF margin | — | -139.0% | -151.8% | -240.4% | -176.0% |
| Return on assets | 3.7% | -31.9% | -36.2% | -29.4% | -16.3% |
| Return on equity | 11.0% | -202.3% | -269.0% | -173.1% | -28.6% |
| Debt / equity | 0.88× | 2.55× | 2.70× | 1.83× | 0.19× |
| Current ratio | 2.49 | 1.27 | 1.38 | 1.80 | 3.43 |
| Revenue growth | 9.7% | -31.8% | 11.6% | 10.1% | 50.9% |
Source: SEC EDGAR filings · CIK 0001429260 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.